VivoSeq
Oncology

Non-Muscle Invasive Bladder Cancer With Carcinoma in Situ

4

Pipeline Programs↗

1

Active Trials↗

4

Companies Involved↗

Non-muscle Invasive Bladder Cancer With Carcinoma in Situ is an early-stage landscape with 4 programs across 4 companies. The most active players are Ferring, Johnson & Johnson, Avyxa. 4 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

25/100

Pipeline Velocity

0/100

Mech. Concentration

33/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Ferring logo

Ferring

1 program

Phase 3Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 3A

Avyxa

1 program

Phase 3Merck & Co. logo

Merck & Co.

1 program

Phase 3

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 34

Nadofaragene Firadenovec

Ferring

Gemcitabine

Johnson & Johnson

Docetaxel

Avyxa

Pembrolizumab

Merck & Co.

Approved
No programs

Analysis

Modality Breakdown

4programs
Small molecule250%
Monoclonal antibody125%
Gene therapy125%

Modality classified for 100% of 4 pipeline programs.

Analysis

Trial Status

1

clinical trials

Recruiting1 · 100%

Clinical Trials

Trial Activity

A Phase 3, Randomised, Multi-center, Open Label Trial to Evaluate the Safety and Efficacy of Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade Bacillus Calmette-Guerin Therapy (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC)
Recruiting·Ferring logoFerring·Phase 3·NCT06545955·250 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)